Thrombosis and Hemostasis Research

Thrombosis is a crucial hemostatic process for maintaining blood volume (hemostasis) following injury, yet aberrant thrombosis can trigger pathological conditions including myocardial infarction and stroke. Therefore the initiation of thrombosis is tightly controlled under physiological conditions.

Products for Thrombosis and Hemostasis Research - Page 2

Cat.No. Product Name Information/Activity
BCC6229 LDV FITC 1207610-07-8
BCC6332 Leukadherin 1 Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18.
BCC3943 MNS MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
BCC7458 OGT 2115 OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.
BCC6275 P11 848644-86-0
BCC6105 PM 102 1234564-95-4
BCC7694 RGDS peptide Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
BCC7894 RWJ 50271 RWJ 50271 is an selective inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells).
BCC6216 TC-I 15 916734-43-5
BCC6080 TCS 2314 TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.

Thrombosis and Hemostasis Research

Thrombosis and Hemostasis Research Products Targets

Products for Thrombosis and Hemostasis Research - Page 2